NCT01574300

Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 136 (actual)
• Sponsor: Addario Lung Cancer Medical Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to facilitate application of the known biomarkers to patients presenting today, and to establish a collection of biospecimens that will be useful for discovering and validating new biomarkers for future use.

Detailed description

Because of the historically poor outcomes of lung cancer patients, suboptimal therapeutic efficacy, and significant side effects of chemotherapy, and the need to choose more efficacious treatment regimens, and patients most likely to benefit from them, there is a need to predict a priori whether an individual patient's tumor will respond to a particular therapeutic agent. However, virtually all lung cancer tumor samples available today are from resection specimens so direct, intra-patient molecular-clinical therapy correlations are impossible. Without the critical mass of tissue and data necessary to identify optimal molecular targets for lung cancer and drugs active against these targets, new discoveries that offer the only hope of long-term survival for many lung cancer patients remain elusive. This study facilitates the collection of biospecimens from advanced lung cancer patients and routine determination of a panel of documented clinically significant biomarkers. In addition, it will centrally integrate and standardize research tissue samples with corresponding proteomic, genomic, molecular and clinical data across a multitude of institutions and oncology networks

Conditions

• Non-small Cell Lung Cancer Metastatic
• Small Cell Lung Carcinoma

Interventions

Type	Name	Description
OTHER	therapeutic interventions	All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics

Timeline

• Start date: 2010-11-01
• Primary completion: 2019-03-01
• Completion: 2019-03-01
• First posted: 2012-04-10
• Last updated: 2020-01-10